Aldeyra Therapeutics
ALDX

$4.15

1.47%

Market Cap: 247M

About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Employees: 10

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 4 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

289% more call options, than puts

Call options by funds: $871K | Put options by funds: $224K

0.41% more ownership

Funds ownership: 59.7% [Q4 2023] → 60.11% (+0.41%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

6% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 33

4% less funds holding

Funds holding: 104 [Q4 2023] → 100 (-4) [Q1 2024]

6% less capital invested

Capital invested by funds: $124M [Q4 2023] → $116M (-$7.74M) [Q1 2024]

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$10

141%

upside

Avg. target

$10

141%

upside

High target

$10

141%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Francois Brisebois	141%upside $10	Outperform Reiterated	6 May 2024
HC Wainwright & Co. Matthew Caufield	141%upside $10	Buy Reiterated	6 May 2024
Oppenheimer Francois Brisebois	141%upside $10	Outperform Upgraded	3 Apr 2024
HC Wainwright & Co. Matthew Caufield	141%upside $10	Buy Reinstated	2 Apr 2024

See Analyst Rankings

Financial journalist opinion

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled to begin at 8:00 a.m. ET today. Pipeline Updates Following positive biomarker results in adults, including near-normalization o.

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the completion of enrollment in a Phase 3 dry eye chamber clinical trial of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease. The trial is designed to enable potential resubmission of a dry eye dise.

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Aldeyra Therapeutics to Host Investor Roundtable Q&A

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that the company will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024 at 8:00 a.m. ET. The call will include prepared remarks from Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, followed by a Q&A session.

Aldeyra Therapeutics to Host Investor Roundtable Q&A

Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission

Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical and clinical trials for the treatment of dry eye disease and allergic conjunctivitis. Aldeyra plans to resubmit Reproxalap's new drug application by Q4 2024, with potential FDA approval by Q2 2025, which could trigger potential milestone payments and revenue opportunities.

Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference. Dr. Brady's conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jeff.

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

Zacks Investment Research

Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Teva Pharmaceutical Industries Ltd. (TEVA) have performed compared to their sector so far this year.

Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced enrollment of the first patient in a Phase 3 dry eye chamber clinical trial designed to enable a potential resubmission of the New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye.

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024

Aldeyra Therapeutics (NASDAQ: ALDX ) just reported results for the first quarter of 2024. Aldeyra Therapeutics reported earnings per share of -14 cents.

ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa. Aldeyra will present new preclinical data from investigational RASP modulators in animal models for obesity, atopic dermatitis, inflammatory pain, and alcoholic h.

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

Zacks Investment Research

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

See News Rankings